By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
Preview - This content has been restricted to logged in users only.
To enhance the bioavailability of poorly soluble drugs in BCS Class II, formulators often work with amorphous forms, which are many times more soluble.
In their efforts to enhance the bioavailability of poorly soluble drugs in BCS Class II, formulators often work with amorphous forms, which are many times more soluble than crystals of the same substance. The problem is, how can the amorphous drug be preserved, even though its natural tendency is to crystallise? One way is to prepare it as a solid dispersion.
